These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27291296)

  • 1. Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor.
    Goldgof GM; Durrant JD; Ottilie S; Vigil E; Allen KE; Gunawan F; Kostylev M; Henderson KA; Yang J; Schenken J; LaMonte GM; Manary MJ; Murao A; Nachon M; Murray R; Prescott M; McNamara CW; Slayman CW; Amaro RE; Suzuki Y; Winzeler EA
    Sci Rep; 2016 Jun; 6():27806. PubMed ID: 27291296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4.
    Turner H
    Future Med Chem; 2016; 8(2):227-38. PubMed ID: 26824174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs.
    Spillman NJ; Kirk K
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):149-62. PubMed ID: 26401486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials.
    Spillman NJ; Allen RJ; McNamara CW; Yeung BK; Winzeler EA; Diagana TT; Kirk K
    Cell Host Microbe; 2013 Feb; 13(2):227-37. PubMed ID: 23414762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials.
    Dennis ASM; Lehane AM; Ridgway MC; Holleran JP; Kirk K
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials.
    Flannery EL; McNamara CW; Kim SW; Kato TS; Li F; Teng CH; Gagaring K; Manary MJ; Barboa R; Meister S; Kuhen K; Vinetz JM; Chatterjee AK; Winzeler EA
    ACS Chem Biol; 2015 Feb; 10(2):413-20. PubMed ID: 25322084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical characterization and chemical inhibition of PfATP4-associated Na
    Rosling JEO; Ridgway MC; Summers RL; Kirk K; Lehane AM
    J Biol Chem; 2018 Aug; 293(34):13327-13337. PubMed ID: 29986883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609.
    Zhang R; Suwanarusk R; Malleret B; Cooke BM; Nosten F; Lau YL; Dao M; Lim CT; Renia L; Tan KS; Russell B
    J Infect Dis; 2016 Jan; 213(1):100-4. PubMed ID: 26136472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound.
    Bouwman SA; Zoleko-Manego R; Renner KC; Schmitt EK; Mombo-Ngoma G; Grobusch MP
    Travel Med Infect Dis; 2020; 36():101765. PubMed ID: 32561392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites.
    Chavchich M; Van Breda K; Rowcliffe K; Diagana TT; Edstein MD
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5167-74. PubMed ID: 27297484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spiroindolones, a potent compound class for the treatment of malaria.
    Rottmann M; McNamara C; Yeung BK; Lee MC; Zou B; Russell B; Seitz P; Plouffe DM; Dharia NV; Tan J; Cohen SB; Spencer KR; González-Páez GE; Lakshminarayana SB; Goh A; Suwanarusk R; Jegla T; Schmitt EK; Beck HP; Brun R; Nosten F; Renia L; Dartois V; Keller TH; Fidock DA; Winzeler EA; Diagana TT
    Science; 2010 Sep; 329(5996):1175-80. PubMed ID: 20813948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
    González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
    Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Search for novel
    Reghunandanan K; T P A; Krishnan N; K M D; Prasad R; Nelson-Sathi S; Chandramohanadas R
    J Biomol Struct Dyn; 2024 Aug; 42(12):6200-6211. PubMed ID: 37424150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yeast-based high-throughput screen identifies Plasmodium falciparum equilibrative nucleoside transporter 1 inhibitors that kill malaria parasites.
    Frame IJ; Deniskin R; Rinderspacher A; Katz F; Deng SX; Moir RD; Adjalley SH; Coburn-Flynn O; Fidock DA; Willis IM; Landry DW; Akabas MH
    ACS Chem Biol; 2015 Mar; 10(3):775-83. PubMed ID: 25602169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse chemotypes disrupt ion homeostasis in the Malaria parasite.
    Lehane AM; Ridgway MC; Baker E; Kirk K
    Mol Microbiol; 2014 Oct; 94(2):327-39. PubMed ID: 25145582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective Total Synthesis of KAE609 via Direct Catalytic Asymmetric Alkynylation to Ketimine.
    Takada H; Kumagai N; Shibasaki M
    Org Lett; 2015 Oct; 17(19):4762-5. PubMed ID: 26367505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic responses in blood-stage malaria parasites associated with increased and decreased sensitivity to PfATP4 inhibitors.
    Tewari SG; Elahi R; Kwan B; Rajaram K; Bhatnagar S; Reifman J; Prigge ST; Vaidya AB; Wallqvist A
    Malar J; 2023 Feb; 22(1):56. PubMed ID: 36788578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria.
    Schmitt EK; Ndayisaba G; Yeka A; Asante KP; Grobusch MP; Karita E; Mugerwa H; Asiimwe S; Oduro A; Fofana B; Doumbia S; Su G; Csermak Renner K; Venishetty VK; Sayyed S; Straimer J; Demin I; Barsainya S; Boulton C; Gandhi P
    Clin Infect Dis; 2022 May; 74(10):1831-1839. PubMed ID: 34410358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconstructing the Qo site of Plasmodium falciparum bc 1 complex in the yeast enzyme.
    Vallières C; Fisher N; Meunier B
    PLoS One; 2013; 8(8):e71726. PubMed ID: 23951230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
    Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
    Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.